We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Science & Health > Content Piece

Shimadzu, Cure Pharmaceutical and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products

Published: Oct 27, 2017   
Listen with
Speechify
0:00
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

Shimadzu announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.

 

Shimadzu, Cure Pharmaceutical Corp and CK Sciences will be researching and profiling the synergistic effects of the cannabinoids and terpenes often referred to as the “Entourage Effect.” The organizations will be using Shimadzu’s Cannabis Analyzer for Potency, a high performance liquid chromatograph (HPLC) designed specifically for quantitative determination of cannabinoid content, as well as a headspace Gas Chromatograph Mass Spectrometer (GCMS) for terpene profiling. Shimadzu will train laboratory personnel and be a single-source contact for technical support. Cure/CK Sciences will utilize these instruments to demonstrate their performance capabilities and generate data for the purpose of validating cannabis as a viable pharmaceutical treatment.

 

"When we dove head first into pharmaceutical cannabis research, we knew we needed to start outfitting our lab to be ready for what was to come,” said Tracy Ryan, CEO & Founder, CK Sciences. “When we met with Shimadzu, and we saw their passion for our mission, we knew we were in incredible hands! When analyzing cannabis everything has to be so precise. With Shimadzu's platforms and team of brilliant scientists supporting our efforts, we have already set ourselves up for success.”

 

“The emerging pharmaceutical cannabis market requires dedicated, thoughtful leaders eager to showcase the pharmaceutical benefits of cannabis on a scientific level,” said Bob Clifford, Ph.D., General Manager of Marketing, Shimadzu Scientific Instruments. “The Cure/CK Sciences group has continuously demonstrated such a leadership commitment, and we’re excited about the opportunities this agreement provides.”


This article has been republished from materials provided by Shimadzu. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement